The extracellular domain of the (pro)renin receptor [(P)RR] is cleaved to generate the soluble form of (P)RR [s(P)RR]. Multiple clinical studies have revealed the association between serum/plasma s(P)RR levels and certain diseases, thereby suggesting a potential role for s(P)RR as a disease biomarker. Here, we investigated whether site-1 protease (S1P) is responsible for cleaving (P)RR to generate s(P)RR. Reduction of endogenous S1P with siRNA attenuated s(P)RR generation in Chinese hamster ovary (CHO) cells exogenously expressing human (P)RR with a C-terminal decahistidine tag [CHO/h(P)RR-10His cells]; conversely, overexpression of S1P by transient transfection increased s(P)RR generation. The S1P inhibitor PF429242 suppressed s(P)RR generation in CHO/h(P)RR-10His and human cervical carcinoma HeLa cells; however, the ADAM inhibitor GM6001 had no effect. The furin inhibitor Dec-RVKR-CMK had no effect on the amount of s(P)RR, but caused a slight increase in the size of the s(P)RR. Moreover, the reversible vesicle-trafficking inhibitor brefeldin A (BFA) enhanced the generation of large-sized s(P)RR; PF429242, but not Dec-RVKR-CMK, suppressed this BFA-induced s(P)RR formation. The size of s(P)RR generated during BFA treatment was reduced after removal of BFA; Dec-RVKR-CMK, but not PF429242, suppressed this conversion. Together, these results suggest that s(P)RR is generated by sequential processing by S1P and furin.
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The (pro)renin receptor [(P)RR] is a modulator of the reninangiotensin system that is essential for maintaining blood pressure and electrolyte balance (1) . (P)RR is related to renal, cardiac and retinal damage associated with hypertension and diabetes (27) . In addition to its role as the cell surface receptor for renin and prorenin, (P)RR functions in vacuolar H + -ATPase (V-ATPase) function (8, 9) and Wnt/ b-catenin signalling (10, 11) .
Although (P)RR is synthesized as a single-spanning transmembrane protein (1), 28-kDa soluble (P)RR [s(P)RR] was detected in the plasma (12) and urine (13) . Multiple clinical studies have revealed the association between s(P)RR levels and diseases, such as preeclampsia (1416), gestational diabetes (17) , small size for gestational age of birth (18) , chronic kidney disease (19) , renal dysfunction in patients with heart failure or essential hypertension (20, 21) and pancreatic ductal adenocarcinoma (11) , thereby suggesting a potential role for s(P)RR as a diseases biomarker.
Cousin et al. (12) reported that s(P)RR is generated by intracellular cleavage of full-length (P)RR by furin in the trans-Golgi; this process also produces a C-terminal membrane-bound fragment, M8-9 (22) (Fig. 1) . In contrast, other report has shown that (P)RR is cleaved by ADAM19 instead of furin in the Golgi apparatus (23) . Furin is a member of the subtilisin-like proprotein convertase family involved in the processing of a wide variety of precursor proteins (24, 25) . The consensus sequence for preferential cleavage by furin is R-X-(K/R)-R# (where X represents any amino acid) (26) ; however, the R-X-X-R site is cleaved with lower efficiency (27) . Full-length human (P)RR is thought to be cleaved by furin at the R 275 -K-T-R 278 # site (12), which is highly conserved among species (Fig. 1 ). ADAM19 is a transmembrane metalloprotease with functions in protein ectodomain shedding (28) . Although the secondary structure of the substrate is thought to be important for cleavage by ADAM19, the particular consensus sequence for cleavage remains unclear (28) .
The N-terminal sequences of the M8-9 fragment were reported in bovines to be E 282 -T-K-Q-V-and D
288
-P-S-T-T-(in human numbering) (22) . However, these sequences are not consistent with the proposed furin cleavage site (Fig. 1) . We found that the R-X-I-L sequence motif immediately upstream to the E 282 -T-K-Q-V-is conserved among species (Fig. 1) . Moreover, we noticed that this motif corresponded to the consensus sequence for cleavage by site-1 protease (S1P): (R/K)-X-(L/I/V)-Z#, where Z represents any amino acid, preferentially Leu or Thr, but excluding Val, Pro, Glu, Asp and Cys (2931). We thus hypothesized that S1P might be another candidate protease responsible for cleaving full-length (P)RR. S1P, also known as subtilisin/kexin isozyme 1 (SKI-1), is a member of the subtilisin-like proprotein convertase family (25, 31) . S1P cleaves membrane-bound transcription factors, such as sterol regulatory element binding proteins (SREBPs) (32), activating transcription factor 6 (ATF6) (33) and cAMP response element binding proteins (CREBs) (3437). It also cleaves membrane-bound enzyme precursors, such as the precursors of GlcNAc-1-phosphotransferase a/b-subunit (30) and S1P itself (38) . S1P also cleaves soluble proteins including pro-brain-derived neurotrophic factor (BDNF) (39) .
In this study, we investigated and obtained evidence for the hypothesis that S1P is responsible for cleaving full-length (P)RR to generate s(P)RR. We also propose a sequential processing model for s(P)RR generation by S1P and furin.
Materials and Methods
Reagents PF429242 was purchased from AdooQ BioScience (Irvine, CA, USA). Furin inhibitor I (Dec-RVKR-CMK) and II (hexa-D-arginine) were purchased from Merck Millipore (Billerica, MA, USA). GM6001 was from Focus Biomolecules (Plymouth Meeting, PA, USA). Brefeldin A (BFA) was from Merck Millipore or Wako Pure Chemical Industries (Osaka, Japan). Cycloheximide was from Nacalai Tesque (Kyoto, Japan). All above reagents except furin inhibitor II were dissolved in dimethyl sulfoxide (DMSO; SigmaAldrich, St. Louis, MO, USA). Furin inhibitor II was dissolved in phosphate-buffered saline (PBS), pH 7.4.
Anti-human (P)RR antibodies (Renin Receptor Antibody; GTX114169) and anti-human S1P antibodies (MBTPS1 Antibody; GTX117475) were purchased from GeneTex (Irvine, CA, USA). 281 of human (P)RR, were obtained from human (P)RR cDNA (40) by PCR and subcloned into the Escherichia coli (E. coli) expression plasmid pET11a (Novagen, Madison, WI, USA) immediately after the initiator methionine codon to generate pET11a-hPRR_N17-R278 and pET11a-hPRR_N17-L281, respectively. E. coli JM109 (DE3) (Promega, Fitchburg, WI, USA) transformed with these plasmids were grown at 37 C to an OD 600 of approximately 0.6 in LB medium containing 50 mg/mL ampicillin. Isopropyl b-D-1-thiogalactopyranoside was added to a final concentration of 1 mM, and the cultures were incubated for an additional 3 h. E. coli cells were harvested by centrifugation at 13,200 Â g for 5 min, sonicated in 20 mM phosphate buffer (pH 7.4) and centrifuged at 13,200 Â g for 5 min. The resulting precipitate containing s(P)RR was dissolved in SDS-PAGE sample buffer containing 2-mercapthoethanol and incubated at 95 C for 5 min.
Recombinant s(P)RR production in Escherichia coli

Cell culture
Human cervical carcinoma HeLa cells (RBRC-RCB0007) were provided by the RIKEN BRC through the National Bio-Resource Project of the MEXT, Japan and maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin at 37 C in 5% CO 2 . Chinese hamster ovary (CHO) cells stably expressing human (P)RR with a C-terminal decahistidine tag [CHO/h(P)RR-10His] (40) were maintained in DMEM supplemented with 2.5% dialyzed fetal bovine serum, 2 mM L-glutamine, 100 U/mL penicillin, 100 mg/ mL streptomycin, 100 mM non-essential amino acids and 1 mM methotrexate (Sigma-Aldrich) at 37 C in 5% CO 2 .
Small-interfering RNA (siRNA)-mediated reduction of S1P expression in CHO/h(P)RR-10His cells We used human S1P siRNA (Silencer select validated siRNA #s488; Thermo Fisher Scientific, Waltham, MA, USA) to reduce endogenous S1P in CHO cells because the target sequence of this siRNA was identical to the CHO S1P gene sequence. Silencer select negative control #1 siRNA (#4390843) was used as the negative control. CHO/h(P)RR-10His cells were transfected with siRNA using siPORT NeoFX Transfection Agent (Thermo Fisher Scientific) according to the manufacturer's instructions. Briefly, 10 pmol siRNA and the transfection agent were mixed in Opti-MEM I Reduced Serum Medium (Opti-MEM; Thermo Fisher Scientific) and incubated for 10 min. The mixture was distributed into the wells of a 24-well culture plate and overlayed with suspended CHO/h(P)RR10His cells. Forty-eight hours after transfection, the culture medium was replaced with fresh normal medium and the cells were cultured for an additional 24 h. The cells and medium were harvested and then processed for quantitative real-time PCR (qRT-PCR) and immunoblotting as described below. qRT-PCR Total RNA was extracted from the siRNA-transfected CHO/ h(P)RR-10His cells using PureLink RNA Mini Kit (Thermo Fisher Scientific). cDNA synthesis and qRT-PCR were performed using KAPA SYBR FAST One-Step qRT-PCR Kit (KAPA Biosystems, Wilmington, MA, USA) according to the manufacturer's instructions on a MiniOpticon system (Bio-Rad Laboratories, Hercules, CA, USA). Normalization across samples was performed using b-actin mRNA expression. The following primers were used: S1P forward, 5
0 -GCTGTCTGTGTGGAACAT GG-3 0 , and reverse, 5 0 -ACCTCCAATCCTTGGTCCTTG-3 0 ; b-actin forward, 5 0 -CCAAGGCCAACCGTGAAAAG-3 0 , and reverse, 5
0 -GGATCTTCATGAGGTAGTCTGTC-3 0 .
Overexpression of S1P in CHO/h(P)RR-10His cells A DNA fragment encoding human S1P was excised from the human Flexi ORF clone pF1KSDA0091 (Kazusa DNA Research Institute, Chiba, Japan) with BspT104I and PmeI, and subcloned into the mammalian expression plasmid pEBMulti-Hyg (Wako Pure Chemical Industries) digested with ClaI and EcoRV. The resulting plasmid was designated pEBMulti-hS1P. CHO/h(P)RR-10His cells cultured in a 6-well plate for 2427 h were transiently transfected with either pEBMulti-hS1P or pEBMulti-Hyg (as a negative control) by the polyethyleneimine-mediated method (40) . Twenty-four hours after transfection, the culture medium was replaced with fresh normal medium. The cells were cultured for an additional 24 h.
Protease inhibitor treatment CHO/h(P)RR-10His and HeLa cells were grown to confluence in normal medium in 12-well plates. Subsequently, the medium was replaced with fresh normal medium (for CHO cells) or Opti-MEM (for HeLa cells) and treated with DMSO (vehicle), 10 mM PF429242, 50 mM furin inhibitor I or 50 mM GM6001 for 24 h.
BFA treatment CHO/h(P)RR-10His and HeLa cells grown to confluence in 12-well plates were pre-treated with 10 mg/mL cycloheximide in normal medium (for CHO cells) or in Opti-MEM (for HeLa cells) for 6 h to decrease pre-existing cellular s(P)RR. After washing with PBS, the cells were treated with DMSO (vehicle), 10 mM PF429242 or 50 mM furin inhibitor I in fresh medium. One hour later, either DMSO (vehicle) or BFA (final concentration of 10 mg/mL) was added to the medium. The cells were incubated for 1 h.
To investigate the fate of s(P)RR generated during BFA treatment, CHO/h(P)RR-10His cells grown to confluence in 12-well plates were treated with 10 mg/mL BFA in the presence of 10 mg/ mL cycloheximide to block de novo protein synthesis in fresh normal medium for 2 h. Subsequently, the cells were washed with PBS and treated with DMSO (vehicle), 10 mM PF429242, 50 mM furin inhibitor I or 10 mM furin inhibitor II in fresh normal medium containing 10 mg/mL cycloheximide for 4 h.
Preparation of cell lysates and culture supernatants
After the cells were treated as described above, the media were collected and clarified by centrifugation to obtain culture supernatants. The culture supernatants were treated with 80% saturated ammonium sulphate at 25 C for 30 min. The precipitates after centrifugation were dissolved in SDS-PAGE sample buffer containing 2-mercapthoethanol and incubated at 95 C for 5 min. The cells were washed with ice-cold PBS, lysed in SDS-PAGE sample buffer containing 2-mercapthoethanol, and incubated at 95 C for 5 min. For HeLa cells, SDS-PAGE sample buffer containing 2-mercapthoethanol was additionally supplemented with 2.5 U/mL benzonase (Merck Millipore) to digest genomic DNA. Total protein concentrations of the cell lysates were quantified by Bradford assays using XL-Bradford (APRO Life Science Institute, Tokushima, Japan). Samples were analysed by SDS-PAGE followed by immunoblotting as described below.
SDS-PAGE and immunoblot analysis
Proteins in the cell lysates and the culture supernatants were separated by SDS-PAGE on 12% gels and electrotransferred to polyvinylidene difluoride membranes (Merck Millipore). After blocking with 5% (w/v) skim milk in Tris-buffered saline (TBS; 20 mM Tris-HCl, 137 mM NaCl, pH 7.6) at room temperature for 1 h, each membrane was probed with either anti-human (P)RR or antihuman S1P antibodies diluted in Can Get Signal Immunoreaction Enhancer Solution (TOYOBO, Osaka, Japan) at room temperature for 1 h or at 4 C overnight and washed with TBS containing 0.1% Tween 20 (TBS-T). The membranes were further probed with antirabbit IgG-horseradish peroxidase conjugate (#170-6515; Bio-Rad Laboratories) at room temperature for 1 h, washed with TBS-T and processed for detection using hydrogen peroxide and 3,3 0 -diaminobenzidine as the chromogen.
Statistical analyses
Values are presented as means ± SDs. Statistical significance was analysed using two-sided Welch's t-tests. Differences with P values of less than 0.05 were considered significant.
Results
Effects of reduction or overexpression of S1P on cleavage of full-length (P)RR in CHO/h(P)RR-10His cells We previously reported that, in CHO/h(P)RR-10His cells exogenously expressing human (P)RR with a Cterminal decahistidine tag, full-length (P)RR is cleaved by endogenous protease to generate s(P)RR, which is secreted into the culture medium (40) . To determine whether S1P is responsible for the cleavage of fulllength (P)RR, we performed siRNA-mediated reduction of endogenous S1P in this cell line. Because we could not detect endogenous S1P protein by immunoblotting (data not shown), we evaluated the efficacy of the S1P siRNA by measuring the mRNA level of S1P. S1P mRNA levels were reduced to approximately 50% of the control level, as analysed by qRT-PCR ( Fig. 2A) . s(P)RR levels in the cells and culture supernatants were reduced to 0.7-and 0.4-fold of the control level, respectively, as analysed by immunoblotting using anti-(P)RR antibodies (Fig. 2B) , demonstrating that S1P is responsible for cleaving full-length (P)RR to generate s(P)RR.
We next overexpressed human S1P in CHO/ h(P)RR-10His cells by transient transfection (Fig. 3A) . s(P)RR levels in the cells and culture supernatants increased 1.5-and 2-fold, respectively, compared with the control cells transfected with empty plasmid vector (Fig. 3B) . This further supported the hypothesis that S1P is responsible for cleaving fulllength (P)RR to generate s(P)RR.
Effects of protease inhibitors on s(P)RR generation in CHO/h(P)RR-10His and HeLa cells Next, we examined the effects of S1P inhibitor on s(P)RR generation in CHO/h(P)RR-10His cells. Because furin (12) and ADAM19 (23) had been reported to be responsible for s(P)RR generation, we also examined the effects of inhibitors of either furin or ADAM19 to evaluate the possible participation of these proteases. The S1P inhibitor PF429242 markedly reduced the s(P)RR levels in the culture supernatants compared with that of the vehicle-treated control (Fig. 4A) . The ADAM inhibitor GM6001 had little or no effect. Furin inhibitor I did not change s(P)RR levels (Fig. 4A) ; however, the mobility of s(P)RR in the culture supernatant of furin inhibitor I-treated cells was slightly low owing to its increase in molecular mass as compared with those of other treatments (Fig. 4A, lower panel) . Similar results were obtained when endogenous (P)RR was investigated in HeLa cells (Fig. 4B) . These results suggest that S1P is required for cleavage of full-length (P)RR to generate s(P)RR and that furin and ADAMs play little role, if any, in cleaving full-length (P)RR directly.
To investigate the observed differences in mobility of s(P)RR in detail, the cell lysates and culture supernatants were electrophoresed as a mixture in one lane of the gel or separately in an adjacent lane. We observed two discrete s(P)RR bands with low-and high-mobility, which we designated here as type-I and type-II forms, respectively (Fig. 5A ). s(P)RR in the cells and culture supernatants were type-I and type-II forms, respectively, in samples treated with DMSO (vehicle), PF429242 or GM6001. In contrast, in samples treated with furin inhibitor I, s(P)RR in both the cells and culture supernatants was the type-I form, suggesting that furin is responsible for converting the type-I form Fig. 2 Effects of siRNA-mediated reduction of endogenous S1P on the cleavage of full-length (P)RR in CHO/h(P)RR-10His cells. (A) The S1P mRNA levels in CHO/h(P)RR-10His cells treated with either S1P siRNA (siS1P) or negative control siRNA (siNC) were measured by qRT-PCR (n = 3; **P50.005 versus siNC). (B) Whole cell lysates (10 mg of total protein) and culture supernatants (one-quarter of the collected amount) were analysed by SDS-PAGE, followed by immunoblotting using anti-(P)RR antibodies. NS indicates non-specific bands. Graphs in B represent semiquantitative measurements of the full-length (P)RR [FL-(P)RR-10His] and s(P)RR bands using ImageJ software (NIH, Bethesda, MD, USA; n = 3; ***P50.001 versus siNC; ****P50.0005 versus siNC). Representative results of three similar independent experiments are shown. Fig. 3 Effects of overexpression of S1P on the cleavage of full-length (P)RR in CHO/h(P)RR-10His cells. Whole cell lysates (15 mg of total protein) and culture supernatants (one-tenth of the collected amount) prepared from CHO/h(P)RR-10His cells that had been transfected with either the expression plasmid coding for human S1P or the empty plasmid (Vector) were analysed by SDS-PAGE, followed by immunoblotting using either anti-S1P (A) or anti-(P)RR antibodies (B). Representative blots of three independent experiments each with three independent treatments are shown. NS indicates non-specific bands. Graphs represent semiquantitative measurements of the full-length (P)RR [FL-(P)RR-10His] and s(P)RR bands of three independent experiments using ImageJ software (NIH; n = 3/group; *P50.05 versus Vector).
into the type-II form. Type-I and type-II s(P)RRs in CHO/h(P)RR-10His and HeLa cells showed mobility similar to that of recombinant N 17 L 281 and N 17 R 278 s(P)RRs produced in E. coli, respectively (Fig. 5B) . This suggests that the type-I and type-II forms of s(P)RR correspond to s(P)RRs cleaved at the putative cleavage site by S1P (R 278 -T-I-L 281 #) and furin (R 275 -K-T-R 278 #), respectively.
Effects of BFA on s(P)RR generation
To investigate the subcellular location of (P)RR cleavage, we used the vesicle-trafficking inhibitor BFA. BFA reversibly induces the redistribution of the cis-, medial and trans-Golgi proteins to the endoplasmic reticulum (ER), while disrupting the trans-Golgi network (TGN) to the microtubule organizing centre, thereby allowing for dissection of early and late protein transport steps in the secretory pathway (4143). BFA treatment resulted in increased formation of type-I s(P)RR in CHO/h(P)RR-10His and HeLa cells (Fig. 6) . PF429242, but not furin inhibitor I, suppressed this BFA-induced s(P)RR formation to the BFA-untreated control level. s(P)RR was not detected in the culture supernatant of BFA-treated cells (data not shown), consistent with the blockade of protein secretion by BFA (44) . These results indicate that type-I s(P)RR is generated by S1P during the early steps in the secretory pathway. Fig. 4 Effects of protease inhibitors on s(P)RR generation. Whole cell lysates and culture supernatants prepared from CHO/h(P)RR-10His (A) or HeLa cells (B) that had been treated with DMSO alone (Vehicle), PF429242, furin inhibitor I (Furin I) or GM6001 were analysed by SDS-PAGE, followed by immunoblotting using anti-(P)RR antibodies. The immunoblots shown are representative of at least two independent experiments each with three independent treatments. FL-(P)RR, full-length (P)RR; NS, non-specific bands. Graphs represent the s(P)RR levels (for Culture supernatant) or percentage of s(P)RR to total (P)RR levels (for Cell lysate), where total (P)RR is defined as the sum of full-length (P)RR and s(P)RR levels. The intensity of each (P)RR band was measured using ImageJ software (NIH).
Generation of soluble (pro)renin receptor by site-1 protease
We then investigated the fate of type-I s(P)RR generated during BFA treatment in the CHO/ h(P)RR-10His cells. After recovering disrupted vesicular transport by removing BFA, type-II s(P)RR was observed in the culture supernatant and in the cells (Fig. 7, Vehicle) . Cell-permeable furin inhibitor I, but not PF429242, suppressed conversion of the type-I form to the type-II form. However, cell-impermeable furin inhibitor II was unable to block this conversion. These results suggest that furin cleaves type-I s(P)RR intracellularly rather than extracellularly.
Discussion
In the present study, we investigated the hypothesis that S1P is responsible for cleaving full-length (P)RR to generate s(P)RR and provided evidence to support this hypothesis. First, siRNA-mediated reduction of endogenous S1P in CHO/h(P)RR-10His cells attenuated s(P)RR generation (Fig. 2) . Second, overexpression of S1P by transient transfection in this cell line increased s(P)RR generation (Fig. 3) . Third, the S1P inhibitor PF429242 suppressed the generation of s(P)RR in CHO/h(P)RR-10His and HeLa cells (Fig. 4) . Finally, s(P)RR in the cells showed a size similar to that of recombinant N 17 L 281 s(P)RR, which is indicative of cleavage at the predicted S1P cleavage site R 278 -T-I-L 281 # (Fig. 5 ). Whole cell lysates were analysed by SDS-PAGE, followed by immunoblotting using anti-(P)RR antibodies. The immunoblots shown are representative of at least two independent experiments each with three independent treatments. Other indications are the same as in Fig. 4 . Graphs represent the percentage of s(P)RR to total (P)RR levels, where total (P)RR is defined as the sum of full-length (P)RR and s(P)RR levels. The intensity of each (P)RR band was measured using ImageJ software (NIH). R 278 s(P)RR (278) produced in E. coli were analysed by SDS-PAGE, followed by immunoblotting using anti-(P)RR antibodies. C, the cell lysate alone; S, the culture supernatant alone; C + S, mixture of the cell lysate and culture supernatant. Other indications are the same as in Fig. 4 .
Previous studies have suggested that furin (12) or ADAM19 (23) cleaves full-length (P)RR and thus is responsible for s(P)RR generation. However, our protease-inhibitor experiments demonstrated that S1P cleaved full-length (P)RR to generate s(P)RR and that furin and ADAMs played little role, if any, in cleaving full-length (P)RR directly (Fig. 4) . We observed that furin, but not ADAMs, was able to convert s(P)RR (the type-I form) generated by S1P to a shorter form (the type-II form). This furin cleavage most probably occurred at the putative furin cleavage site R 275 -K-T-R 278 # because the type-II s(P)RR showed a size similar to that of recombinant N 17 R 278 s(P)RR (Fig. 5) . Previous in vitro assays using AKTA mutant human (P)RR, in which R 275 and R 278 in the putative furin cleavage site were replaced with Ala, predicted the identical site for furin cleavage (12). Kinouchi et al. (45) observed that AKTA mutant mouse (P)RR was not cleaved by endogenous protease when expressed in mouse embryonic fibroblasts (MEFs); however, overexpression of furin in MEFs did not increase the cleavage of fulllength wild-type (P)RR. Because substituted R 278 (human numbering) in the AKTA mutant corresponds to the critical amino acid for not only furin cleavage (P1 position) but also S1P cleavage (P4 position) (46), these observations suggest that S1P is responsible protease for cleaving full-length (P)RR in MEFs as well.
Subcellular localization of S1P and furin are different en route through the secretory pathway. S1P is localized in the cis-/medial Golgi (47); additional localization to endosomes and lysosomes has also been reported (48) . Furin is mainly localized in the TGN and cycles between the TGN and the cell surface (4951). BFA reversibly induces the redistribution of the cis-, medial and trans-Golgi proteins to the ER and disrupts the TGN to the microtubule organizing centre (4143). BFA treatment causes relocation of S1P to the ER (47) and furin to the microtubule organizing centre (49) . In the present study, BFA treatment increased type-I s(P)RR formation in CHO/h(P)RR10His and HeLa cells (Fig. 6 ). This BFA-induced effect was abolished by treatment with an S1P inhibitor but not by treatment with a furin inhibitor, suggesting that full-length (P)RR localized to the ER (40) was cleaved by S1P that had relocated from the Golgi apparatus. This further suggests that full-length (P)RR is cleaved by S1P at the Golgi apparatus under normal conditions in the absence of BFA. The conversion of type-I s(P)RR to the type-II form was inhibited by a cell-permeable furin inhibitor but not by a cell-impermeable furin inhibitor (Fig. 7) . Although some proteins such as pro-ADAMTS7B (52) and pro-ADAMTS9 (53) were shown to be cleaved by furin at the cell surface, the conversion of type-I s(P)RR to the type-II form most likely occurred in the TGN. Because furin inhibitor I can inhibit furin family proteases, we cannot exclude the possibility that those such as PACE4 (54) , PC6 (55) and PC7 (56) with similar substrate specificity and subcellular localization to furin may be involved in this conversion.
Based on our findings, we propose a sequential processing model for s(P)RR generation (Fig. 8) . In this model, full-length (P)RR is cleaved by S1P at the Golgi apparatus to generate type-I s(P)RR and then further cleaved by furin at the TGN to generate type-II s(P)RR, which is secreted extracellularly. The type-II Generation of soluble (pro)renin receptor by site-1 protease s(P)RR was barely detected in the cells (Fig. 5) , suggesting that this form is secreted immediately after cleavage in the TGN. Type-I s(P)RR was detected in the culture supernatant when cells were treated with a furin inhibitor (Fig. 5) , indicating that furin cleavage is not necessary for secretion of s(P)RR. Therefore, s(P)RR levels can correlate with the expression levels of S1P in certain diseases under conditions in which (P)RR expression levels do not change. We expect that multiple s(P)RR forms may exist in the serum/plasma and urine, and the proportion of these forms may vary in accordance with pathophysiological conditions. The proportion of each s(P)RR form may reflect the cellular expression level and/or activity of the responsible processing enzymes, which may vary according to cell type and cellular condition. Although the physiological and functional significance of this short (three-residue) C-terminal trimming by furin is currently unknown, this difference may provide valuable information to distinguish the cause of increase in serum or plasma s(P)RR levels observed in clinical studies (11, 14, 15, 1721) . S1P gene (Mbtps1) knockout is embryonic lethal in mice (57, 58) , as is (P)RR gene (Atp6ap2) knockout (59) . Liver-specific disruption of S1P in mice has been shown to cause decreased plasma cholesterol and plasma-and liver-triglyceride levels with reduced SREBP target gene expression, revealing that S1P is crucial for cholesterol and fatty acid metabolism (58) . Intriguingly, the presence of interactions between lipid metabolism dysfunction and serum s(P)RR levels was suggested by Morimoto et al. (21) . They found that high-density lipoprotein (HDL)-cholesterol and triglyceride levels showed weak but significantly negative and positive relationships, respectively, with serum s(P)RR levels in patients with essential hypertension. In addition, Lu et al. (60) recently reported that (P)RR regulates low-density lipoprotein (LDL) metabolism by controlling SORT1 and LDL receptor (LDLR) and showed that reduction of (P)RR decreased cellular LDL uptake with reduced SORT1 and LDLR. The recent identification of liver X receptor (LXR), which is known to regulate transcription of target genes governing cholesterol, fatty acid and glucose metabolism, as a transcriptional repressor for inactivation of (P)RR transcription (61) may also support the potential link between lipid metabolism and (P)RR.
Some S1P gene mutations cause phenotypes similar to those of (P)RR gene mutations. The hypomorphic S1P gene mutation woodrat (wrt) causes hypopigmentation independent of hypocholesterolemia in mice (62) , which is similar to that caused by the (P)RR gene mutation pekin (pn) in zebrafish (63) . The S1P gene mutation gonzo (goz) in zebrafish causes cartilage formation defects independent of lipid defects (64) . Cartilage-specific ablation of S1P in mice results in abnormal cartilage independent of the lipid pathway (65) . The (P)RR gene has been identified as an essential gene for chondrocyte differentiation in zebrafish (66) . These observations may suggest the importance of (P)RR cleavage by S1P in pigmentation and cartilage formation. S1P plays an important role in lysosome biogenesis by cleaving the precursor of GlcNAc-1-phosphotransferase a/b-subunit for formation of the mannose 6-phosphate targeting signal on lysosomal enzymes (30) . (P)RR is essential for the biogenesis of active V-ATPase (8, 9) . The present study thus raises the possibility that S1P may play ingenious roles in lysosome biogenesis through targeting of certain enzymes to the lysosomes while concurrently regulating the acidity of this compartment. We should carefully examine whether S1P cleavage is required for active V-ATPase biogenesis because furin cleavage was shown to be dispensable (45) .
Membrane-bound transcription factors constitute a major class of known S1P substrates. Among them are SREBPs (32), ATF6 (33) and CREBs (3437). These proteins are localized in the ER and, upon cholesterol deprivation or ER stress, transported to the Golgi apparatus, where they are cleaved by S1P and further cleaved by site-2 protease to release the active fragment from the membrane (67) . Similarly, transport-dependent cleavage by S1P is thought to be involved in s(P)RR generation because we (Fig. 6 ) and others (23) observed that BFA-treatment increased s(P)RR generation. This possibility, including identification of causative stimuli, should be confirmed in future studies.
The cleavage of full-length (P)RR by S1P at the R-X-I-L# motif is consistent with one of the two N-terminal sequences of the M8-9 fragment, E 282 -T-K-Q-V-(in human numbering), reported in bovines (22) (Fig. 1) . The other, D
288
-P-S-T-T-, is immediately preceded by the sequence K-Q-V-K, which also fits the consensus motif for S1P cleavage [(R/K)-X-(L/I/V)-Z#] (2931). It is possible that the two N-termini of the M8-9 fragment are generated by S1P cleavage in bovines. The corresponding human sequence K 284 -Q-A-K 287 , but not the rat and mouse sequence K-Q-E-N, may serve as a second cleavage site for S1P. In any case, the S1P inhibitor blocked the cleavage of full-length human (P)RR to generate s(P)RR in the present study.
In conclusion, we have provided evidence that S1P is required for cleaving full-length (P)RR to generate s(P)RR. We also proposed a sequential processing model for s(P)RR generation, in which S1P and furin cleave (P)RR sequentially at the Golgi apparatus and TGN, respectively. These findings provide valuable insights into the molecular basis of s(P)RR generation, which may contribute to a better understanding of the pathophysiology of (P)RR. Moreover, these findings may have implications in the diagnosis of diseases involving elevated serum/plasma s(P)RR levels.
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